BioSpace

Accelerating Timelines and Reducing Cost in Early Clinical Drug Development With ICON’s Accelerated Pharmaceutical Solutions

Innovation drives speed in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions integrate advanced ...
Nasdaq

Chemomab Therapeutics Announces FDA Alignment on Phase 3 Trial Design for Nebokitug as Potential First Treatment for Primary Sclerosing Cholangitis

Chemomab Therapeutics has announced that it has successfully completed its End-of-Phase 2 meeting with the FDA, aligning on the design of a single Phase 3 trial for its lead product candidate, ...
Hosted on MSN

Acurx signals progress in Phase 3 ibezapolstat program with $12M credit line following regulatory alignment

David Luci, President and CEO, highlighted several significant developments, including the closing of a $2.5 million registered direct offering and the receipt of positive regulatory guidance from the ...
Investing

CervoMed stock rises after FDA alignment on Phase 3 trial design

"We are very pleased to have achieved alignment with the FDA on key aspects of our Phase 3 design for neflamapimod in DLB, including our selected endpoints and patient enrichment strategy," said Dr.
Morningstar

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

- Flexible Dosing and Extended Duration would be Important Differentiators from Existing Approved Therapies and Other Tyrosine Kinase Inhibitors in Development - ALPHARETTA, Ga., March 06, 2025 (GLOBE ...
Nasdaq

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

- Flexible Dosing and Extended Duration would be Important Differentiators from Existing Approved Therapies and Other Tyrosine Kinase Inhibitors in Development - “We are pleased to report the positive ...